Childhood sexual abuse and paternal death are among the strongest predictors for developing major depressive disorder later ...

Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.

A new analysis included more than 110,000 adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). Patients with TRD had total healthcare costs 1.5 times higher than those ...

Treatment-resistant major depression (TRD) is associated with a 17% higher risk for all-cause mortality than non-TRD major depressive disorder (MDD), a new study shows. The increased mortality risk ...

J&J’s Tamara Werner-Kiechle tells Clinical Trials Arena that the depression landscape needs reframing to ensure optimal ...

As someone who has been involved in psychiatric drug development and clinical strategy for more than two decades, I believe ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD). TRD is defined by a ...

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

Fast Track Designation Highlights the Urgent Need for New Treatment Options and Potential Value of Liafensine SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Denovo Biopharma LLC, a pioneer in applying ...